

NF κ B-p65 (Acetyl Lys221) Polyclonal Antibody

Catalog # AP63262

Product Information

Application	WB, E
Primary Accession	Q04206
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Calculated MW	60219

Additional Information

Gene ID	5970
Other Names	RELA; NF κ B3; Transcription factor p65; Nuclear factor NF- κ -B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3
Dilution	WB~~Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications. E~~N/A
Format	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.
Storage Conditions	-20°C

Protein Information

Name	RELA
Synonyms	NF κ B3
Function	NF- κ -B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- κ -B is a homo- or heterodimeric complex formed by the Rel-like domain- containing proteins RELA/p65, RELB, NF κ B1/p105, NF κ B1/p50, REL and NF κ B2/p52. The heterodimeric RELA-NF κ B1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF- κ -B heterodimeric RELA-NF κ B1 and RELA-REL complexes, for instance, function as transcriptional activators. NF- κ -B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions

with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I- kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I- kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA- binding site which could contribute directly to DNA binding in the NF- kappa-B complex. Besides its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T- cells (PubMed:[15790681](#)). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. Key transcription factor regulating the IFN response during SARS-CoV-2 infection (PubMed:[33440148](#)).

Cellular Location


Nucleus. Cytoplasm Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B) (PubMed:1493333). Colocalized with DDX1 in the nucleus upon TNF induction (PubMed:19058135) Colocalizes with GFI1 in the nucleus after LPS stimulation (PubMed:20547752). Translocation to the nucleus is impaired in L.monocytogenes infection (PubMed:20855622)

Background


NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFkB1/p105, NFkB1/p50, REL and NFkB2/p52. The heterodimeric RELA- NFkB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFkB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Beside its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:[15790681](#)). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin- mediated activation of IL-8 expression.

Images

Western Blot analysis of HepG2-UV, mouse brain cells using Acetyl-NFkB-p65 (K221) Polyclonal Antibody. Antibody was diluted at 1:1000. Secondary antibody was diluted at 1:20000



Western Blot analysis of HEPG2-UV cells using Acetyl-NF κ B-p65 (K221) Polyclonal Antibody diluted at 1 : 1000. Secondary antibody was diluted at 1:20000



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.